Michael Kranda – Chief Executive Officer – Mr. Kranda has over 25 years of biotech operating, finance and corporate development experience. Most recently Mr. Kranda was CEO of Vaccinogen, a cancer vaccine company. Mr. Kranda served as Managing Director of Vulcan Capital for several years, where he led all aspects of their Life Sciences investment efforts and continues to represent them on the PTC board of directors. Mr. Kranda was also the CEO of Oxford GlycoSciences, a pioneer in proteomic based drug and diagnostic product development. Mr. Kranda started his biotech career at Immunex Corporation where he served as President, COO and Director. Mr. Kranda holds a BA and MBA in finance from the University of Washington.
Gregory G, Mahairas, Ph.D. – President & Chief Scientific Officer. Dr. Mahairas holds a doctorate in Immunology and an MS degree in Molecular Microbiology and Microbial genetics. Dr. Mahairas has over 19 years of scientific leadership experience and is an expert in scientific management, scale-up, and process development. Dr. Mahairas was Chief Technology Officer of VieVax Corporation, Chief of Operations for Regulome Corporation, and Director of the University of Washington High Throughput Sequencing Center. Teams under the direction of Dr. Mahairas mapped and sequenced the rice, corn and soybean genomes and were major contributors to the Human Genome sequencing project. He has made major scientific contributions in the genomics of human, plants and microbes, and, the pathogenesis of tuberculosis, staphylococcus, and mycoplasma infectious disease.
BEATBio BOARD OF DIRECTORS
Michael Kranda – Chief Executive Officer.
Gregory G. Mahairas, Ph.D. – President & Chief Scientific Officer.
Jim Leggett, M.D. (Chairman) – Dr. Leggett is the Medical Director of the Diagnostic Vascular Laboratory at Overlake Internal Medicine Associates, and, Medical Director of the Hope Heart Institute. Dr. Leggett received his MD from the University of Arkansas Medical Sciences Center, and his internal medicine and cardiology training at the University of Washington and University of New Mexico School of Medicine respectively. Dr. Leggett is board certified in internal medicine and cardiovascular medicine, and is an expert in the treatment of cardiovascular disease, and non-invasive and invasive techniques to treat coronary and peripheral artery disease.
Craig Tall – Mr. Tall is the managing director of CET Capital Partners LLC, which provides assistance in mergers and acquisitions, financing strategies and other financial matters. Prior to founding CET Capital Partners, he served as Vice Chairman of Washington Mutual Inc. from1999 to 2004 and before that, beginning in 1985, as Executive Vice President of corporate development for Washington Mutual. Earlier in his career he was President and owner of an employee benefits consulting firm. He presently holds board positions for a diverse group of companies, including The Space Needle Corporation, True Blue Inc. (NYSE), Cascadia Capital and Vittana (a not-for-profit global micro student lender). Craig holds a B.S. in Economics from the University of Pennsylvania’s Wharton School.
Charles E. Murry, M.D., Ph.D. – Scientific co-founder and Chairman of the Scientific Advisory Board. Dr. Murry is Professor of Pathology, Bioengineering and Medicine/Cardiology and Director of the Center for Cardiovascular Biology at the University of Washington. Dr. Murry is one of the foremost experts in cardiac repair, cardiac stem cells and tissue regeneration.
Buddy Ratner, Ph.D. – Scientific co-founder and Scientific Advisory Board member. Professor of Bioengineering and Chemical engineering, and, Director of the University of Washington Engineered Biomaterials. Dr. Ratner is a National Academy of Engineering member and is one of the most highly regarded experts in the area of bioengineering and biomaterials.
Michael Laflamme, M.D., Ph.D. – Scientific co-founder and Scientific Advisory Board member. Associate Professor of Pathology, University of Washington Center for Cardiovascular Biology. Dr. Laflamme is a leader in the field of cardiac physiology, stem cell-derived cardiac tissues and cardiac pacemaker cells.
Michael Regnier, Ph.D. – Scientific co-founder and Scientific Advisory Board Member. Dr. Regnier is Professor and Vice Chairman of the department of Bioengineering at the University of Washington. Dr. Regnier leads the Heart and Muscle Mechanics laboratory in the Department of Bioengineering and is an expert in cardiac and skeletal muscle physiology, muscle dysfunction with disease and development of gene and cell therapies. He is an established Investigator of the American Heart Association, and an Affiliate Investigator of the Benaroya Research Institute. Dr. Regnier holds a Ph.D. in Biology and Neurobiology from the University of Southern California.
Mark Reisman MD – Dr. Reisman is the Director of Swedish Medical Center Cardiac catheterization laboratory, Partner with Seattle Heart and Vascular Consultants, and, President of the Seattle Science Foundation. He is a Professor of Medicine at the University of Washington and co-chair of the Clinical Outcomes Assessment Program of the State of Washington. Dr. Reisman is board certified in cardiology and has been Principal Investigator for dozens of clinical trials. Dr. Reisman holds a Bachelors Degree from SUNY – Stonybrook, and a Medical Degree from the Sackler Medical School, New York, NY. He did an internship in Internal Medicine at the Robert Wood Johnson Medical Center in Brunswick NJ, a Fellowship in Cardiology at St. Lukes Medical Center in New York, NY, and, a Fellowship in Interventional Cardiology at UC San Diego Medical Center.
Jane Lebkowski Ph.D. – Dr Lebkowski was recently the Chief Scientific Officer of Geron Corporation. Prior to Geron she was Vice president of Discovery Research at Rhone-Poulenc Rorer and Vice President of R&D at Applied Immune Sciences. Dr. Lebkowski holds a Ph.D. in Biochemistry from Princeton University and is an internationally recognized expert in stem cell biology and regenerative medicine. She has authored over 70 peer – reviewed papers and 12 issued US Patents.
Barrie Carter, Ph.D. – Dr. Carter was the Executive Vice President and Chief Scientific Officer of Targeted Genetics Corporation from 1992 until 2008. Previously, he was at the National Institutes of Health (NIH) for 22 years serving as Chief of the Laboratory of Molecular and Cellular Biology in the National Institute for Diabetes and Digestive and Kidney Diseases from 1982 to 1992. He received his B.Sc. with Honors from the University of Otago, Dunedin, New Zealand and his Ph.D. in the Biochemistry Department of the University of Otago Medical School. Dr. Carter’s long-term research interests are in the molecular biology of viruses, development of AAV vectors and gene therapy. Dr. Carter serves on the editorial boards of Human Gene Therapy and Virology from 1995-2000. Dr. Carter currently serves as a member of the Advisory Committee to the Director of NIH and is a member of the Board of Directors of the American Society for Gene Therapy.
Michael Kotlikoff, VMD, Ph. D. – Dr. Kotlikoff is the Austin O. Hooey Dean of the College of Veterinary Medicine, School of Biomedical Sciences at Cornell University. Dr. Kotlikoff received his VMD from the University of Pennsylvania, Philadelphia, and, his Ph.D. in Physiology from the University of California, Davis. Dr. Kotlikoff is a renowned expert in intercellular communication and generation of spontaneous electrical activity, excitation-contraction coupling and rhythmicity in cardiac and smooth muscle cells.
Michael Simons, MD - Dr. Simons is the Robert W. Berliner Professor of Medicine, and, Chief of Cardiovascular Medicine at Yale University School of Medicine, and, Yale-New Haven Hospital. Dr. Simons received his M.D. degree from Yale School of Medicine, and his B.S. Degree from the Massachusetts Institute of Technology. Dr. Simons is an expert in Angiogenesis, vascular development, and cardiovascular disease.